Matthew J Everly

5PUBLICATIONS
8CO-AUTHORS
Major global burdens of diseaseImmunogenetics (incl. genetic immunology)Pharmaceutical delivery technologiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 25, 2019
Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials.

Intan Purnajo, Jennifer L Beaumont, Martin Polinsky

|Jan 01, 2019
Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study.

Carrie A Schinstock, Darshana M Dadhania, Matthew J Everly

|Dec 15, 2018
The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement.

Mark D Stegall, Kenneth Troy Somerville, Matthew J Everly

|Nov 10, 2018
Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.

Carrie A Schinstock, Andrew J Bentall, Byron H Smith

|Feb 18, 2017
Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.

Matthew J Everly, Kimberly P Briley, Carl E Haisch

Pageof 1